Clinical Psychiatry News - Bupropion wins approval for SAD.(seasonal affective disorder)
Extended-release bupropion is the first drug to be approved by the Food and Drug Administration for patients with seasonal affective disorder.
The FDA approved the antidepressant last month for preventing major depressive episodes in patients with a history of seasonal affective disorder (SAD). Previously, no drug had been approved for preventing or treating SAD, although antidepressants have been used in such patients.
Related Results
Smoking cessation drug may be helpful for nicotine addiction in schizophrenics.
Steady-state clinical pharmacokinetics of bupropion extended-release in youth…
Sporting Digest: drugs in sport
BCMA Calls for Tobacco Tax to Fund Stop-Smoking Programs.
Biovail Announces Receipt Of An Approvable Letter For Wellbutrin XL.
Bupropion “can help patients with [seasonal affective disorder] to avoid the depressive symptoms and impaired functioning that typically affect them in …
Read the rest of this article with a Free Trial at HighBeam Research.
